'Non-criteria' antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort
| Autor: | Jialin Teng, Junna Ye, Qiongyi Hu, Liyan Wan, Yue Sun, Yutong Su, Xue-Feng Wang, Tingting Liu, Honglei Liu, Xiaobing Cheng, Jieyu Gu, Chengde Yang, Hui Shi, Jinfeng Zhou, Gary L. Norman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty lcsh:Diseases of the musculoskeletal system IgA isotype Gastroenterology Anti-phosphatidylserine/prothrombin antibodies Cohort Studies 03 medical and health sciences 0302 clinical medicine Asian People Antiphospholipid syndrome Internal medicine Medicine Humans Adverse effect 030203 arthritis & rheumatology Autoimmune disease Pregnancy Lupus anticoagulant Non-criteria antiphospholipid antibodies biology business.industry Middle Aged medicine.disease Rheumatology Anti-β2-glycoprotein I Domain 1 030104 developmental biology Case-Control Studies Cohort biology.protein Antibodies Antiphospholipid Female Antibody lcsh:RC925-935 business Research Article |
| Zdroj: | Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020) Arthritis Research & Therapy |
| ISSN: | 1478-6362 |
| DOI: | 10.1186/s13075-020-2131-4 |
| Popis: | Background Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS) classification criteria to include IgG/IgM anti-β2-glycoprotein (aβ2GPI) antibodies in addition to IgG/IgM anti-cardiolipin antibodies (aCL) and lupus anticoagulant (LAC), some individuals with clinical features of APS remain seronegative (seronegative APS or SNAPS) and are at risk of recurrent thrombosis and pregnancy morbidities. Our aim was to assess the value of “non-criteria” aPL antibodies to detect these SNAPS patients. Methods One hundred ninety-two APS patients, 90 SNAPS patients, 193 autoimmune disease controls, and 120 healthy controls were evaluated. Ten antiphospholipid antibodies (aPLs) were tested using commercial kits, including 5 non-criteria aPLs: anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, aCL IgA, aβ2GPI IgA, and anti-β2GPI Domain 1 (aβ2GPI-D1) IgG. Results Up to 60.9% of the SNAPS and 93.5% of APS patients were detected by at least one non-criteria aPL. aPS/PT IgG had the highest Youden index in classifying APS and SNAPS from controls. aPS/PT IgG and aβ2GPI Domain 1 IgG seem to be the most significant risk factors for thrombotic events and pregnancy morbidity, respectively. aPS/PT IgG/IgM and aβ2GPI-D1 IgG were detected in some SNAPS patients, while IgA isotypes of aCL/aβ2GPI tended to appear together with other biomarkers. The combined analysis showed enhanced diagnostic performance with the inclusion of non-criteria aPLs. Conclusions Recognition of SNAPS patients is critical for clinical management and prevention of potential thrombotic and obstetric adverse events. The non-criteria antiphospholipid antibodies help to identify a considerable portion (60.9%) of these patients who otherwise may remain untreated and at clinical risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink